November 12, 2002
Natural or synthetic secretin does not reduce symptoms of autism, study shows
Secretin, touted as a possible cure for autism just three years ago, is not a magic bullet that relieves the symptoms of the developmental disorder, report researchers at the University of Washington and the University of Colorado Health Sciences Center.
Their study, which involved the largest and most-comprehensive trials of the hormone yet conducted, is published in the November issue of Journal of the American Academy of Child Adolescent Psychiatry.
“The message to parents is that there is no evidence that secretin is effective and should be given to children with autism,” said Geraldine Dawson, director of the UW’s Autism Center, who co-led the study. “We have yet to find a medicine that cures autism, and the results really underscore why research for the cause of autism is necessary.”
The study is believed to be the first to measure the effectiveness of both natural porcine secretin and a synthetic form of the hormone and a placebo. Secretin is a naturally occurring human hormone produced in the small intestine that helps control digestion and is used in diagnosing gastrointestinal problems.
Autism is a disorder that interferes with a child’s ability to communicate and relate socially with other people. Afflicted individuals also can have a restricted range of activities and interests, and about 75 percent of children with autism also have some form of mental retardation. The disorder is far more common than previously thought, affecting more than half a million Americans.
The researchers found that neither form of secretin reduced the symptoms of autism beyond the effects noted for the placebo.
“With autism we know there is a very large placebo effect, so you have to show a bigger effect to say a treatment worked,” said Dawson. “We don’t fully understand the mystery of the placebo effect in medicine. But the expectancy that a treatment will work can have a real positive impact. It is not an imagined effect, but real change because of the expectancy of some possible change.”
In the study, 85 children diagnosed with autism and ranging in age from 3 to 12 were each given a single intravenous injection of one type of secretin or a placebo in randomized, double-blind trials.
The children were evaluated on a number of factors, including language, social functioning and behavior problems by parents, teachers and researchers one week before receiving the injection and again four weeks after being injected. None of those doing the evaluations knew what type of injection each child received. Parents were asked about their child’s behavioral and sleep problems and their vocabulary, while teachers were primarily asked about behavior problems. In laboratories, investigators rated and diagnosed the children in a play-based interaction that tested social and communication functioning. The children also were given a vocabulary test.
In addition, the researchers compared children with and without gastrointestinal problems, common symptoms for many people with autism. The initial report claiming benefits from secretin in the late 1990s came from a study in which the hormone was used in diagnosing a child’s gastrointestinal problems. Again, Dawson said, the new study showed there was no response beyond that shown from the placebo.
“Secretin is not a magic bullet,” she said. “When parents first heard about the initial reports some were paying huge sums of money for secretin treatment. The National Institutes of Health decided to commission this study in response to a high visibility case where parents were using a treatment that had not been assessed. The available evidence suggests there is no role for secretin.
“There is still a possibility that repeated doses of secretin might have an effect. But we think parents should use treatments that we know are effective, such as behavioral interventions and, in some cases, drugs to treat associated symptoms such as attention problems and hyperactivity that affect many children with autism.”
Other members of the research team included Dr. Alan Unis, a former UW professor of psychiatry and behavior science; Jeff Munson, a research scientist in the UW’s autism research program; Julie Osterling, clinical director of the UW’s Autism Center; Robert Abbott, UW professor of educational psychology; Dr. Ed Goldson, professor of pediatrics at the University of Colorado Health Sciences Center; Sally Rogers, professor of psychiatry at the Colorado center and JFK Partners; and Robin Gabriels, a psychologist at the Colorado center and JFK Partners.
###
For more information, contact Dawson at (206) 543-1051 or dawson@u.washington.edu
